ES2738100T3 - Método de fabricación de una vacuna contra micoplasma - Google Patents
Método de fabricación de una vacuna contra micoplasma Download PDFInfo
- Publication number
- ES2738100T3 ES2738100T3 ES13817835T ES13817835T ES2738100T3 ES 2738100 T3 ES2738100 T3 ES 2738100T3 ES 13817835 T ES13817835 T ES 13817835T ES 13817835 T ES13817835 T ES 13817835T ES 2738100 T3 ES2738100 T3 ES 2738100T3
- Authority
- ES
- Spain
- Prior art keywords
- mycoplasma
- mycoplasma bacteria
- antigen
- culture
- manufacturing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/70—Non-animal cells
Abstract
Un método para la preparación de una composición inmunogénica para el tratamiento y/o la profilaxis de infecciones por micoplasma en un sujeto que comprende: a.) cultivo de bacterias micoplasma en un sistema de células eucariotas reducido en suero, en el que dicho sistema de células eucariotas comprende una estirpe celular MDCK o una estirpe celular Mc Coy; b.) obtención de un antígeno de las bacterias micoplasma; y c.) adición de un vehículo farmacéuticamente aceptable, en el que la composición inmunogénica comprende bacterias micoplasma seleccionadas entre la lista que contiene: M. hyopneumoniae, M. hyorhinis y M. hyosynoviae y, en el que el antígeno es una bacterina inactivada completa, en el que el cultivo de las bacterias micoplasma en el sistema de células eucariotas incluye concentraciones de suero entre el 0-10 % (v/v).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261746997P | 2012-12-28 | 2012-12-28 | |
| PCT/US2013/076807 WO2014105672A1 (en) | 2012-12-28 | 2013-12-20 | Method of making a mycoplasma vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2738100T3 true ES2738100T3 (es) | 2020-01-20 |
Family
ID=49917778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13817835T Active ES2738100T3 (es) | 2012-12-28 | 2013-12-20 | Método de fabricación de una vacuna contra micoplasma |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9273281B2 (es) |
| EP (1) | EP2938747B1 (es) |
| JP (2) | JP6122146B2 (es) |
| KR (1) | KR102153275B1 (es) |
| CN (2) | CN104968365B (es) |
| AR (1) | AR094648A1 (es) |
| AU (1) | AU2013370983B2 (es) |
| BR (1) | BR112015012711B1 (es) |
| CA (1) | CA2896298C (es) |
| CL (1) | CL2015001562A1 (es) |
| DK (1) | DK2938747T3 (es) |
| EA (1) | EA032772B1 (es) |
| ES (1) | ES2738100T3 (es) |
| HU (1) | HUE045015T2 (es) |
| MX (1) | MX361273B (es) |
| MY (1) | MY173223A (es) |
| PH (1) | PH12015501333A1 (es) |
| PL (1) | PL2938747T3 (es) |
| PT (1) | PT2938747T (es) |
| SG (2) | SG11201505089YA (es) |
| TW (2) | TWI618542B (es) |
| UA (1) | UA121193C2 (es) |
| WO (1) | WO2014105672A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8546149B2 (en) | 2010-08-27 | 2013-10-01 | Intervet Inc. | Potency test for vaccine formulations |
| EP2938356B1 (en) * | 2012-12-28 | 2020-05-13 | Boehringer Ingelheim Vetmedica GmbH | Immunogenic composition comprising mycoplasma antigens |
| CN104968365B (zh) * | 2012-12-28 | 2018-04-03 | 勃林格殷格翰动物保健有限公司 | 支原体疫苗的制备方法 |
| CN105441368B (zh) * | 2016-01-19 | 2019-01-01 | 福清市默克兽医院 | 一株牛支原体及其应用 |
| WO2017132578A1 (en) * | 2016-01-29 | 2017-08-03 | Advanced Animal Diagnostics, Inc. | Methods and compositions for detecting mycoplasma exposure |
| EP3778626A1 (en) * | 2016-08-09 | 2021-02-17 | Agricultural Technology Research Institute | Composition for preventing and treating mycoplasma hyorhinis infection, and method for producing said composition |
| EP3576799A4 (en) * | 2017-02-03 | 2020-12-30 | The Administrators of The Tulane Educational Fund | OPHTHALMIC COMPOSITIONS FOR THERAPY AND PROPHYLAXIS |
| CN110650989B (zh) | 2017-05-24 | 2023-03-31 | 三菱化学株式会社 | 成型材料、及纤维增强复合材料 |
| MX2021015170A (es) | 2019-06-10 | 2022-03-22 | Elanco Us Inc | Formulaciones de medios de micoplasma. |
| CN113201050B (zh) * | 2020-08-06 | 2022-07-22 | 青岛诺安百特生物技术有限公司 | 一种金黄色葡萄球菌噬菌体穿孔素及其制备方法和应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
| GB1074920A (en) * | 1965-04-21 | 1967-07-05 | Pfizer & Co C | Growth medium for mycoplasma pneumoniae and vaccine production |
| ES343655A1 (es) * | 1966-07-11 | 1968-09-01 | Research Corp | Metodo para la preparacion de un inoculo para aves de co- rral. |
| JPS5540568B2 (es) | 1972-10-05 | 1980-10-18 | ||
| US5338543A (en) | 1992-02-27 | 1994-08-16 | Ambico, Inc. | Thimerosal inactivated mycoplasma hyopneumoniae vaccine |
| US5885823A (en) | 1995-06-05 | 1999-03-23 | Nobl Laboratories, Inc. | Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents |
| KR100797547B1 (ko) * | 2000-03-03 | 2008-01-24 | 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 | 무혈청 배양 및 부유 배양에서 사용할 수 있는 세포 및상기 세포를 사용하여 백신용 바이러스를 제조하는 방법 |
| JP3402304B2 (ja) * | 2000-03-30 | 2003-05-06 | 株式会社微生物化学研究所 | 猫クラミジアワクチンの製造方法 |
| US7018638B2 (en) | 2000-12-19 | 2006-03-28 | Wyeth | Mycoplasma hyopneumoniae bacterin vaccine |
| MY129765A (en) | 2000-12-19 | 2007-04-30 | Wyeth Corp | Improved mycoplasma hyopneumoniae bacterin vaccine |
| CA2452666A1 (en) | 2001-07-02 | 2003-01-16 | Pfizer Products Inc. | Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle |
| US20030147914A1 (en) | 2001-07-02 | 2003-08-07 | Pfizer Inc. | Mycoplasma bovis vaccine and methods of reducing pneumonia in animals |
| ATE412426T2 (de) | 2001-07-02 | 2008-11-15 | Pfizer Prod Inc | Vakzination in einer dosis mit i mycoplasma hyopneumoniae /i |
| PL368826A1 (en) | 2001-08-28 | 2005-04-04 | Pfizer Products Inc. | Mycoplasma bovis challenge model, methods for administering m. bovis and methods for inducing pneumonic lung lesions |
| TWI238721B (en) * | 2003-06-20 | 2005-09-01 | Animal Technology Inst Taiwan | Swine enzootic vaccine, its producing method and usage |
| WO2006084364A1 (en) | 2005-02-09 | 2006-08-17 | Magna International Inc. | Method of manufacturing a semi-structural panel |
| WO2006095431A1 (ja) * | 2005-03-10 | 2006-09-14 | Kyoritsu Seiyaku Corporation | 動物由来の成分なしで培養可能である細胞株及びその作出方法、これを用いたウイルスの生産方法、及びワクチンの生産方法 |
| WO2007042827A2 (en) * | 2005-10-14 | 2007-04-19 | Ivan Petyaev | Treatment and diagnosis of obligate intracellular pathogens |
| EP2615167A1 (en) | 2006-09-15 | 2013-07-17 | MedImmune, LLC | Method for eliminating DNA contaminants from viral preparations |
| US20090068231A1 (en) | 2007-09-11 | 2009-03-12 | Wyeth | Live attenuated mycoplasma strains |
| AR069087A1 (es) | 2007-10-29 | 2009-12-30 | Boehringer Ingelheim Vetmed | Cepa bacteriana de m. bovis atenuada avirulenta obtenida por pases, vacuna de micoplasma boris y metodos de uso de la misma |
| MX2010005014A (es) | 2007-11-06 | 2010-06-30 | Wyeth Llc | Vacuna viva avirulenta de mycoplasma hyopneumoniae con adyuvante. |
| US20090317423A1 (en) | 2008-01-23 | 2009-12-24 | Boehringer Ingelheim Vetmedica, Inc. | Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions |
| US8444989B1 (en) | 2008-04-18 | 2013-05-21 | Boehringer Ingelheim Vetmedica Gmbh | One dose vaccination against mycoplasma infections of pigs |
| WO2009142086A1 (ja) | 2008-05-23 | 2009-11-26 | 学校法人久留米大学 | マイコプラズマ感染症用ワクチン組成物 |
| DK2310046T3 (da) | 2008-06-27 | 2016-04-25 | Zoetis Services Llc | Hidtil ukendte adjuvanssammensætninger |
| WO2010051210A1 (en) | 2008-10-31 | 2010-05-06 | Boehringer Ingelheim Vetmedica, Inc. | Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition |
| MX2011012362A (es) | 2009-05-19 | 2012-04-19 | Bioproperties Pty Ltd | Cepa de vacuna de mycoplasma hyopneumoniae sensible a la temperatura y usoz de la misma. |
| US20110150770A1 (en) | 2009-12-18 | 2011-06-23 | Boehringer Ingelheim Vetmedica, Inc. | Multivalent vaccine against porcine teschovirus and other disease causing organisms in swine |
| US8112663B2 (en) | 2010-03-26 | 2012-02-07 | Lsi Corporation | Method to establish redundancy and fault tolerance better than RAID level 6 without using parity |
| CN102258776B (zh) | 2011-07-07 | 2013-07-10 | 普莱柯生物工程股份有限公司 | 猪肺炎支原体、猪鼻支原体二联灭活疫苗及其制备方法 |
| UA114503C2 (uk) | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv та mycoplasma hyopneumoniae |
| UA114504C2 (uk) | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs |
| US9120859B2 (en) | 2012-04-04 | 2015-09-01 | Zoetis Services Llc | Mycoplasma hyopneumoniae vaccine |
| EP2938356B1 (en) | 2012-12-28 | 2020-05-13 | Boehringer Ingelheim Vetmedica GmbH | Immunogenic composition comprising mycoplasma antigens |
| CN104968365B (zh) | 2012-12-28 | 2018-04-03 | 勃林格殷格翰动物保健有限公司 | 支原体疫苗的制备方法 |
-
2013
- 2013-12-20 CN CN201380066001.XA patent/CN104968365B/zh active Active
- 2013-12-20 US US14/135,796 patent/US9273281B2/en active Active
- 2013-12-20 EP EP13817835.5A patent/EP2938747B1/en active Active
- 2013-12-20 UA UAA201507463A patent/UA121193C2/uk unknown
- 2013-12-20 CA CA2896298A patent/CA2896298C/en active Active
- 2013-12-20 HU HUE13817835 patent/HUE045015T2/hu unknown
- 2013-12-20 PL PL13817835T patent/PL2938747T3/pl unknown
- 2013-12-20 EA EA201500701A patent/EA032772B1/ru not_active IP Right Cessation
- 2013-12-20 DK DK13817835.5T patent/DK2938747T3/da active
- 2013-12-20 WO PCT/US2013/076807 patent/WO2014105672A1/en active Application Filing
- 2013-12-20 PT PT13817835T patent/PT2938747T/pt unknown
- 2013-12-20 ES ES13817835T patent/ES2738100T3/es active Active
- 2013-12-20 KR KR1020157020447A patent/KR102153275B1/ko active IP Right Grant
- 2013-12-20 SG SG11201505089YA patent/SG11201505089YA/en unknown
- 2013-12-20 JP JP2015549759A patent/JP6122146B2/ja active Active
- 2013-12-20 BR BR112015012711-8A patent/BR112015012711B1/pt active IP Right Grant
- 2013-12-20 MX MX2015007730A patent/MX361273B/es active IP Right Grant
- 2013-12-20 MY MYPI2015001621A patent/MY173223A/en unknown
- 2013-12-20 CN CN201810161003.1A patent/CN108379571A/zh active Pending
- 2013-12-20 AU AU2013370983A patent/AU2013370983B2/en not_active Ceased
- 2013-12-20 SG SG10201708028VA patent/SG10201708028VA/en unknown
- 2013-12-27 TW TW102148875A patent/TWI618542B/zh active
- 2013-12-27 TW TW107103700A patent/TWI660736B/zh active
- 2013-12-27 AR ARP130105050A patent/AR094648A1/es unknown
-
2015
- 2015-06-05 CL CL2015001562A patent/CL2015001562A1/es unknown
- 2015-06-15 PH PH12015501333A patent/PH12015501333A1/en unknown
-
2016
- 2016-01-19 US US15/000,342 patent/US10512680B2/en active Active
-
2017
- 2017-03-30 JP JP2017067820A patent/JP6449364B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2738100T3 (es) | Método de fabricación de una vacuna contra micoplasma | |
| BR112016022814A8 (pt) | composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico | |
| AR089797A1 (es) | Vacunas contra clostridum difficile que comprenden toxinas recombinantes | |
| GT201600183A (es) | Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas | |
| PH12014502250B1 (en) | Mycoplasma hyopneumoniae vaccine | |
| AR076413A1 (es) | Metodo para atenuar mycoplasma bovis y su vacuna | |
| BR112015009070A2 (pt) | proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas | |
| UY31437A1 (es) | Vacuna de mycoplasma bovis y métodos de uso de la misma | |
| CO6361948A2 (es) | Uso de antigeno de mycoplasma bovis | |
| BR112014032636A2 (pt) | Vacinas atenuadas de streptococcus suis e métodos de produção e usos das mesmas | |
| BR112016023778A2 (pt) | proteína de fusão ou coquetel antígeno, uso de uma proteína de fusão ou coquetel antígeno, vacina, e método para a imunização de um animal, incluindo um ser humano, contra a tuberculose causada por micobactérias virulentas | |
| AR094296A1 (es) | Composicion inmunogenica que comprende antigenos de mycoplasma | |
| CL2017001818A1 (es) | Bacteria de ácido láctico y su uso para el tratamiento de mastitis | |
| EP4241851A3 (en) | Immunogenic compositions | |
| CO7101191A2 (es) | Método de preparación de antobiótico novedoso y sistema de plataforma con base en el mismo | |
| PE20190225A1 (es) | Un metodo para reducir la contaminacion de huevo | |
| NZ717369A (en) | Antibody titer-increasing agent using lactic acid bacterium | |
| BR112018069079A2 (pt) | construtos de alfavírus vivos atenuados e métodos e usos dos mesmos | |
| AR103086A1 (es) | Composiciones y métodos para reducir las infecciones en aves de corral | |
| CL2017002196A1 (es) | Vacuna recombinante contra enteropatía proliferativa en animales. | |
| AR087811A1 (es) | Vacuna contra el staphylococcus aureus | |
| BR112018015255A2 (pt) | extrato de streptococcus uberis como um agente imunogênico | |
| BR112017016437A2 (pt) | ?vacina, uso de um antígeno de lawsonia intracellularis não vivo, e, método para reduzir em um porco a liberação das bactérias lawsonia intracellularis associada com infecção subclínica com lawsonia intracellularis? | |
| CL2014001126A1 (es) | Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec. | |
| BR112017011292A2 (pt) | vacina subunidade, polivalente, altamente imunogênica contra a mastite em mamíferos. |